These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 30159775)

  • 1. Proton pump inhibitors' use and risk of hip fracture: a systematic review and meta-analysis.
    Hussain S; Siddiqui AN; Habib A; Hussain MS; Najmi AK
    Rheumatol Int; 2018 Nov; 38(11):1999-2014. PubMed ID: 30159775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies.
    Poly TN; Islam MM; Yang HC; Wu CC; Li YJ
    Osteoporos Int; 2019 Jan; 30(1):103-114. PubMed ID: 30539272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study.
    Lin SM; Yang SH; Liang CC; Huang HK
    Osteoporos Int; 2018 Jan; 29(1):153-162. PubMed ID: 29032384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proton-pump inhibitors and risk of fractures: an update meta-analysis.
    Zhou B; Huang Y; Li H; Sun W; Liu J
    Osteoporos Int; 2016 Jan; 27(1):339-47. PubMed ID: 26462494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis.
    Ye X; Liu H; Wu C; Qin Y; Zang J; Gao Q; Zhang X; He J
    Eur J Gastroenterol Hepatol; 2011 Sep; 23(9):794-800. PubMed ID: 21701389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term proton pump inhibitor use and risk of osteoporosis and hip fractures: A nationwide population-based and multicenter cohort study using a common data model.
    Park DH; Seo SI; Lee KJ; Kim J; Kim Y; Seo WW; Lee HS; Shin WG; Yoo JJ
    J Gastroenterol Hepatol; 2022 Aug; 37(8):1534-1543. PubMed ID: 35501296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies.
    Ngamruengphong S; Leontiadis GI; Radhi S; Dentino A; Nugent K
    Am J Gastroenterol; 2011 Jul; 106(7):1209-18; quiz 1219. PubMed ID: 21483462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proton pump inhibitor use is associated with hip fracture development: a nationwide population-based cohort study.
    Min YW; Lee YC; Kim K; Ryu S; Hong KS; Jeon HH; Kim YS; Park JH; Son HJ; Rhee PL
    Korean J Intern Med; 2020 Sep; 35(5):1084-1093. PubMed ID: 31671930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss.
    Targownik LE; Lix LM; Leung S; Leslie WD
    Gastroenterology; 2010 Mar; 138(3):896-904. PubMed ID: 19931262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors.
    Kaye JA; Jick H
    Pharmacotherapy; 2008 Aug; 28(8):951-9. PubMed ID: 18657011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of proton pump inhibitors and risk of fragility hip fracture in a Mediterranean region.
    Reyes C; Formiga F; Coderch M; Hoyo J; Ferriz G; Casanovas J; Monteserín R; Brotons C; Rojas M; Moral I
    Bone; 2013 Feb; 52(2):557-61. PubMed ID: 23023097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No association between proton pump inhibitor use and risk of dementia: Evidence from a meta-analysis.
    Hussain S; Singh A; Zameer S; Jamali MC; Baxi H; Rahman SO; Alam M; Altamish M; Singh AK; Anil D; Hussain MS; Ahmad A; Najmi AK
    J Gastroenterol Hepatol; 2020 Jan; 35(1):19-28. PubMed ID: 31334885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term proton pump inhibitor therapy and risk of hip fracture.
    Yang YX; Lewis JD; Epstein S; Metz DC
    JAMA; 2006 Dec; 296(24):2947-53. PubMed ID: 17190895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study.
    Khalili H; Huang ES; Jacobson BC; Camargo CA; Feskanich D; Chan AT
    BMJ; 2012 Jan; 344():e372. PubMed ID: 22294756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proton pump inhibitors therapy and risk of bone diseases: An update meta-analysis.
    Liu J; Li X; Fan L; Yang J; Wang J; Sun J; Wang Z
    Life Sci; 2019 Feb; 218():213-223. PubMed ID: 30605646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proton Pump Inhibitors' Use and Risk of Iron Deficiency Anaemia: A Systematic Review and Meta-analysis.
    Ali MD
    Curr Rev Clin Exp Pharmacol; 2023; 18(2):158-166. PubMed ID: 35255801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proton pump inhibitor use and risk of hip fracture in patients with type 2 diabetes.
    Chou YS; Jiang HJ; Chen CH; Ho PS; Lee TC
    Sci Rep; 2020 Aug; 10(1):14081. PubMed ID: 32826941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proton Pump Inhibitor Use and Risk of Hip Fracture in Kidney Transplant Recipients.
    Lenihan CR; Sukumaran Nair S; Vangala C; Ramanathan V; Montez-Rath ME; Winkelmayer WC
    Am J Kidney Dis; 2017 May; 69(5):595-601. PubMed ID: 27866965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proton-pump inhibitor use and hip fractures in men: a population-based case-control study.
    Adams AL; Black MH; Zhang JL; Shi JM; Jacobsen SJ
    Ann Epidemiol; 2014 Apr; 24(4):286-90. PubMed ID: 24507954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients.
    Corley DA; Kubo A; Zhao W; Quesenberry C
    Gastroenterology; 2010 Jul; 139(1):93-101. PubMed ID: 20353792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.